他汀治疗对老年人认知下降与痴呆发生的影响
本研究纳入18,846名≥65岁、无既往心血管事件、无重大躯体残疾或痴呆的随机试验参与者,随访4.7年,分析基线他汀使用与痴呆、轻度认知障碍(MCI)及认知域变化的关系。结果显示他汀使用与痴呆、MCI及其亚型或认知功能评分变化均无显著关联(所有p>0.05),亲脂性与亲水性他汀间也无差异。基线神经认知能力是他汀与痴呆及记忆变化关联的效应修饰因素。
要点
- 在≥65岁无痴呆老年人中,他汀使用与痴呆或MCI发生无显著关联。
- 他汀使用与各认知域评分随时间变化无显著关联。
- 亲脂性与亲水性他汀对认知结局的影响无差异。
核心结论
- 在≥65岁成人中,他汀治疗与痴呆、MCI或各认知域下降无显著关联。
研究设计与样本
- 基于阿司匹林随机试验的二次分析,纳入18,846名≥65岁、无既往心血管事件、无重大躯体残疾或痴呆的参与者,随访4.7年。
主要发现
- 他汀使用与非使用相比,痴呆、MCI及其亚型以及认知功能评分随时间变化均无显著关联(所有p>0.05)。
- 亲脂性与亲水性他汀使用者之间任何结局均无差异。
- 基线神经认知能力是他汀与痴呆关联的效应修饰因素(交互p<0.001),也是与记忆变化关联的效应修饰因素(交互p=0.02)。
临床怎么用
- 对于≥65岁无痴呆老年人,他汀治疗无需因担忧认知下降或痴呆风险而调整。
局限性
- 研究为观察性分析,结果需等待正在进行的随机试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The neurocognitive effect of statins in older adults remain uncertain. OBJECTIVES: The aim of this study was to investigate the associations of statin use with cognitive decline and incident dementia among older adults. METHODS: This analysis included 18,846 participants ≥65 years of age in a randomized trial of aspirin, who had no prior cardiovascular events, major physical disability, or dementia initially and were followed for 4.7 years. Outcome measures included incident dementia and its subclassifications (probable Alzheimer's disease, mixed presentations); mild cognitive impairment (MCI) and its subclassifications (MCI consistent with Alzheimer's disease, other MCI); and changes in domain-specific cognition, including global cognition, memory, language and executive function, psychomotor speed, and the composite of these domains. Associations of baseline statin use versus nonuse with dementia and MCI outcomes were examined using Cox proportional hazards models and with cognitive change using linear mixed-effects models, adjusting for potential confounders. The impact of statin lipophilicity on these associations was further examined, and effect modifiers were identified. RESULTS: Statin use versus nonuse was not associated with dementia, MCI, or their subclassifications or with changes in cognitive function scores over time (p > 0.05 for all). No differences were found in any outcomes between hydrophilic and lipophilic statin users. Baseline neurocognitive ability was an effect modifier for the associations of statins with dementia (p for interaction < 0.001) and memory change (p for interaction = 0.02). CONCLUSIONS: In adults ≥65 years of age, statin therapy was not associated with incident dementia, MCI, or declines in individual cognition domains. These findings await confirmation from ongoing randomized trials.
引用
- Zhou Z, Ryan J, Ernst ME, et al. Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. J Am Coll Cardiol. 2021. PMID: 34167639. doi:10.1016/j.jacc.2021.04.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。